LX102 / Innostellar Biotherap - LARVOL DELTA

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Innostellar Biotherapeutics Co.,Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Innostellar Biotherapeutics Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: May 2029 ➔ Oct 2029

Enrollment closed • Trial completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Subretinal LX102 gene therapy for neovascular age-related macular degeneration (nAMD): 9-month follow-up of a phase 1 clinical trial (ARVO 2024) - "Subretinal LX102 injection was well tolerated in nAMD subjects. And these results support LX102 gene therapy as a potential treatment option to reduce the burden of frequent anti-VEGF treatments and maintain the best long-term visual outcomes."

Clinical • Gene therapy • P1 data • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Subretinal LX102 gene therapy for neovascular age-related macular degeneration (nAMD): 1 year follow-up of an investigator initiated trial (ARVO 2024) - "Subretinal LX102 injection was well tolerated in nAMD subjects. And these results support LX102 gene therapy as a potential treatment option to reduce the burden of anti-VEGF treatments and maintain long-term visual outcomes."

Gene therapy • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration